Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Oligodendroglioma 2Central Nervous System Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Optic Nerve Glioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Choroid Plexus Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 3Docetaxel 3Watchful Waiting 2Tamoxifen 2Immunohistochemistry 2Goserelin 2Everolimus 2Cyclophosphamide 2Bevacizumab 2Anastrozole 2vandetanib 1pegfilgrastim 1lonafarnib 1exemestane 1Trastuzumab 1Sunitinib 1Psychiatric Rehabilitation 1Neoadjuvant Therapy 1Metformin 1Mental Status and Dementia Tests 1Leuprolide 1Letrozole 1Lapatinib 1High-Energy Shock Waves 1Gene Expression Profiling 1Doxorubicin 1Dasatinib 1Chemotherapy, Adjuvant 1Biopsy, Needle 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms, Male × lonafarnib × Clear all
NCT00068757 2012-09-12

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Completed
23 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡